Cargando…

ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6

BACKGROUND: The purpose of this study was to assess the concordance of real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection of ESR1, PGR, ERBB2, and MKi67 messenger RNA (mRNA) in breast cancer tissues with central immunohistochemistry (IHC) in women treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filipits, M., Rudas, M., Singer, C.F., Fitzal, F., Bago-Horvath, Z., Greil, R., Balic, M., Lax, S.F., Halper, S., Hulla, W., Wu, N.C., Liu, X., Weidler, J., Bates, M., Hlauschek, D., Gnant, M., Dubsky, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358421/ https://www.ncbi.nlm.nih.gov/pubmed/34371382 http://dx.doi.org/10.1016/j.esmoop.2021.100228

Ejemplares similares

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial
por: Fitzal, F, et al.
Publicado: (2021)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
por: Gnant, M, et al.
Publicado: (2013)

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
por: Pfeiler, G, et al.
Publicado: (2013)

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial
por: Bjelic-Radisic, V., et al.
Publicado: (2020)

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18
por: Minichsdorfer, C., et al.
Publicado: (2022)

Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment
por: Erber, Ramona, et al.
Publicado: (2021)

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies
por: Breyer, Johannes, et al.
Publicado: (2017)

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®
por: Varga, Zsuzsanna, et al.
Publicado: (2017)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

MKI UFOs at Injection
por: Baer, T, et al.
Publicado: (2011)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens
por: Laible, Mark, et al.
Publicado: (2016)

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer
por: Singer, Christian F., et al.
Publicado: (2022)

Disrupted PGR-B and ESR1 signaling underlies defective decidualization linked to severe preeclampsia
por: Garrido-Gomez, Tamara, et al.
Publicado: (2021)

Brain metastases free survival differs between breast cancer subtypes
por: Berghoff, A, et al.
Publicado: (2012)

Crystal Structures of Human CaMKIα Reveal Insights into the Regulation Mechanism of CaMKI
por: Zha, Manwu, et al.
Publicado: (2012)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

MKI performance during 2016 and plans for EYETS
por: Barnes, M J, et al.
Publicado: (2017)

HL-LHC kicker magnet (MKI)
por: Brice, Maximilien
Publicado: (2018)

Installation of the first MKI for the HL-LHC
por: Brice, Maximilien
Publicado: (2023)

MKI’s alumina tube discrimination and optimisation
por: Maurin, Theo
Publicado: (2021)

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
por: Blank, Patricia R., et al.
Publicado: (2014)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
por: Tendl-Schulz, Kristina A., et al.
Publicado: (2020)

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer
por: Kriegmair, M.C., et al.
Publicado: (2018)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

NRIP1 is activated by C-JUN/C-FOS and activates the expression of PGR, ESR1 and CCND1 in luminal A breast cancer
por: Binato, Renata, et al.
Publicado: (2021)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

MKI67 as a potential diagnostic biomarker in pulmonary hypertension
por: Zhou, Huiling, et al.
Publicado: (2022)

Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy
por: Schindl, M., et al.
Publicado: (2018)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials
por: Krois, Wilfried, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_62mt95nv63m2n98dmq9absunjq